Ballast Advisors LLC Has $1.08 Million Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Ballast Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,741 shares of the medical research company’s stock after purchasing an additional 25 shares during the quarter. Ballast Advisors LLC’s holdings in Thermo Fisher Scientific were worth $1,077,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Foster & Motley Inc. raised its stake in Thermo Fisher Scientific by 2.4% in the third quarter. Foster & Motley Inc. now owns 5,971 shares of the medical research company’s stock valued at $3,693,000 after purchasing an additional 141 shares in the last quarter. Harvest Portfolios Group Inc. increased its holdings in Thermo Fisher Scientific by 0.6% in the 3rd quarter. Harvest Portfolios Group Inc. now owns 91,540 shares of the medical research company’s stock valued at $56,624,000 after buying an additional 583 shares during the period. Catalina Capital Group LLC lifted its holdings in shares of Thermo Fisher Scientific by 16.6% during the 3rd quarter. Catalina Capital Group LLC now owns 1,044 shares of the medical research company’s stock worth $646,000 after acquiring an additional 149 shares during the period. Fiduciary Family Office LLC boosted its position in shares of Thermo Fisher Scientific by 2.4% during the 3rd quarter. Fiduciary Family Office LLC now owns 1,594 shares of the medical research company’s stock worth $986,000 after acquiring an additional 38 shares in the last quarter. Finally, Cornerstone Capital Inc. raised its position in Thermo Fisher Scientific by 1.2% during the third quarter. Cornerstone Capital Inc. now owns 52,085 shares of the medical research company’s stock valued at $32,218,000 after purchasing an additional 615 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on TMO. Bernstein Bank raised their target price on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a report on Tuesday, October 22nd. Barclays decreased their target price on Thermo Fisher Scientific from $620.00 to $610.00 and set an “equal weight” rating on the stock in a research report on Wednesday, October 23rd. Morgan Stanley increased their target price on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the stock an “overweight” rating in a report on Friday, September 20th. Wells Fargo & Company lowered their price objective on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating for the company in a research report on Thursday, October 24th. Finally, UBS Group raised shares of Thermo Fisher Scientific to a “strong-buy” rating in a research note on Monday, September 16th. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus target price of $649.33.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $554.29, for a total transaction of $5,542,900.00. Following the transaction, the chief executive officer now owns 121,192 shares in the company, valued at approximately $67,175,513.68. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the completion of the sale, the executive vice president now directly owns 16,663 shares of the company’s stock, valued at $9,333,946.08. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $554.29, for a total value of $5,542,900.00. Following the transaction, the chief executive officer now owns 121,192 shares of the company’s stock, valued at $67,175,513.68. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,150 shares of company stock valued at $10,094,925 over the last ninety days. 0.34% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $559.65 on Wednesday. The company has a quick ratio of 1.26, a current ratio of 1.63 and a debt-to-equity ratio of 0.64. The company has a market capitalization of $214.07 billion, a PE ratio of 35.16, a P/E/G ratio of 3.67 and a beta of 0.79. The firm has a fifty day simple moving average of $597.40 and a 200 day simple moving average of $583.97. Thermo Fisher Scientific Inc. has a twelve month low of $437.26 and a twelve month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last released its earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping the consensus estimate of $5.25 by $0.03. The business had revenue of $10.60 billion during the quarter, compared to analysts’ expectations of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The firm’s revenue was up .2% on a year-over-year basis. During the same quarter last year, the firm posted $5.69 earnings per share. On average, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current year.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.